With approval, acoramaidis (Attruby; BridgeBio Pharma) becomes the first agent with a label specifying near-complete ...

The FDA has approved Attruby, a new oral treatment that helps reduce heart-related deaths and hospital visits among adults ...

It is a fictional representation created for illustrative purposes only. The U.S. Food and Drug Administration has announced ...

Acoramidis becomes the second drug ever approved for this condition, based on the results of the ATTRibute-CM trial.

Biohaven said on Monday its experimental treatment for a rare neuromuscular disorder failed to significantly improve motor function in a late-stage trial, sending the shares of rival Scholar Rock, ...

BofA raised the firm’s price target on BridgeBio (BBIO) to $45 from $42 and keeps a Buy rating on the shares after the company announced the ...

In a report released yesterday, Tiago Fauth from Wells Fargo maintained a Buy rating on BridgeBio Pharma (BBIO – Research Report), with a price ...

Attruby (acoramidis) is a small molecule approved to treat adults with transthyretin amyloid cardiomyopathy. It will have a ...

Attruby (acoramidis), a near complete TTR stabilizer, has been approved by FDA to reduce cardiovascular death and ...

(In Nov. 22 story, corrects list price of Pfizer's drug to about $268,000 from $225,000 in paragraph 3) (Reuters) -The U.S.

The FDA has accepted Alnylam’s supplemental New Drug Application for Amvuttra on the heels of BridgeBio’s Attruby nod, ...